Current Therapeutic Strategies in Clinical Urology

Alice Crane, Sudhir Isharwal, Hui Zhu

Research output: Contribution to journalArticle

Abstract

The field of urology encompasses all benign and malignant disorders of the urinary tract and the male genital tract. Urological disorders convey a huge economic and patient quality-of-life burden. Hospital acquired urinary tract infections, in particular, are under scrutiny as a measure of hospital quality. Given the prevalence of these pathologies, there is much progress still to be made in available therapeutic options in order to minimize side effects and provide effective care. Current drug delivery mechanisms in urological malignancy and the benign urological conditions of overactive bladder (OAB), interstitial cystitis/bladder pain syndrome (IC/BPS), and urinary tract infection (UTI) will be reviewed herein. Both systemic and local therapies will be discussed including sustained release formulations, nanocarriers, hydrogels and other reservoir systems, as well as gene and immunotherapy. The primary focus of this review is on agents which have passed the preclinical stages of development.

Original languageEnglish (US)
Pages (from-to)3010-3019
Number of pages10
JournalMolecular Pharmaceutics
Volume15
Issue number8
DOIs
StatePublished - Aug 6 2018
Externally publishedYes

Keywords

  • bladder cancer
  • hydrogels
  • interstitial cystitis
  • intravesical therapy
  • kidney cancer
  • nanocarriers
  • overactive bladder
  • prostate cancer
  • urinary tract infection

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmaceutical Science
  • Drug Discovery

Fingerprint Dive into the research topics of 'Current Therapeutic Strategies in Clinical Urology'. Together they form a unique fingerprint.

  • Cite this